Lizardo-Thiebaud, María JoséMaría JoséLizardo-ThiebaudCervantes-Álvarez, EduardoEduardoCervantes-ÁlvarezLimón-de la Rosa, NathalyNathalyLimón-de la RosaTejeda Domínguez, FaridFaridTejeda DomínguezPalacios-Jiménez, MildredMildredPalacios-JiménezMéndez-Guerrero, OsvelyOsvelyMéndez-GuerreroDelaye-Martínez, MarcoMarcoDelaye-MartínezRodríguez-Álvarez, FátimaFátimaRodríguez-ÁlvarezRomero-Morales, BeatrizBeatrizRomero-MoralesWei-Hui, LiuLiuWei-HuiHuang, Christene A.Christene A.HuangKershenobich, DavidDavidKershenobichNavarro Álvarez, NaluNaluNavarro Álvarez2022-11-242022-11-242020https://scripta.up.edu.mx/handle/20.500.12552/213110.1055/s-0040-1715108Liver injury can result from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with more than one-third of COVID-19 patients exhibiting elevated liver enzymes. Microvesicular steatosis, inflammation, vascular congestion, and thrombosis in the liver have been described in autopsy samples from COVID-19 patients. Several factors, including direct cytopathic effect of the virus, immune-mediated collateral damage, or an exacerbation of preexisting liver disease may contribute to liver pathology in COVID-19. Due to its immunological functions, the liver is an organ likely to participate in the viral response against SARS-CoV-2 and this may predispose it to injury. A better understanding of the mechanism contributing to liver injury is needed to develop and implement early measures to prevent serious liver damage in patients suffering from COVID-19. This review summarizes current reports of SARS-CoV-2 with an emphasis on how direct infection and subsequent severe inflammatory response may contribute to liver injury in patients with and without preexisting liver disease. © 2020 American Institute of Physics Inc.. All rights reserved.enResource Types::text::journal::journal article